Optimal supportive therapy with BP and proteinuria control is pivotal in treating patients with IgA nephropathy.
Suboptimal treatment of hypertension and proteinuria persisted in many patients with IgA nephropathy in the Cure Glomerulonephropathy Network study.
Many patients had above-target proteinuria despite optimal BP control and may benefit from novel therapies or clinical trials.